Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Change in Inventory (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Change in Inventory for 16 consecutive years, with -$637000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Inventory fell 195.36% to -$637000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$4.6 million, a 535.31% decrease, with the full-year FY2024 number at $64000.0, up 104.2% from a year prior.
  • Change in Inventory was -$637000.0 for Q3 2025 at Harvard Bioscience, up from -$977000.0 in the prior quarter.
  • In the past five years, Change in Inventory ranged from a high of $1.9 million in Q2 2021 to a low of -$2.4 million in Q4 2024.
  • A 5-year average of $98157.9 and a median of $292000.0 in 2023 define the central range for Change in Inventory.
  • Peak YoY movement for Change in Inventory: soared 5033.33% in 2021, then plummeted 253.61% in 2022.
  • Harvard Bioscience's Change in Inventory stood at $1.8 million in 2021, then plummeted by 132.05% to -$581000.0 in 2022, then tumbled by 132.53% to -$1.4 million in 2023, then tumbled by 74.09% to -$2.4 million in 2024, then soared by 72.92% to -$637000.0 in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Change in Inventory are -$637000.0 (Q3 2025), -$977000.0 (Q2 2025), and -$670000.0 (Q1 2025).